LLY · Earnings call · 2026Q3T · Full report

Strategic Initiatives

ELI LILLY & Co · 2026-10-29 · Importance 34 · Surprise 42

Management described a portfolio approach to obesity treatment, citing approximately 110 million people in the U.S. with obesity or overweight and a larger international population. It said Foundayo, tirzepatide, retatrutide, selective amylin medicines, and Olora-TZP could serve different patient needs and treatment stages. Lilly aims to offer these medicines through a consistent platform that lets patients start, switch, and step up to the treatment that works best for them.

Key facts

• The FDA approved pirtobrutinib for certain patients with previously untreated CLL or SLL; it reduced progression or death risk by 80% versus bendamustine plus rituximab.
• Lilly planned to begin Phase 3 trials of co-formulated Olora-TZP imminently and anticipated a slower, optimized dose-escalation schedule to improve tolerability.
• The FDA approved tirzepatide to reduce cardiovascular risk in adults with type 2 diabetes.
• The FDA approved once-weekly basal insulin efsitora alfa for adults with type 2 diabetes under the brand name Onswik.
• Lilly initiated a Phase 3 trial of tarsalisib in combination with a CDK4/6 inhibitor and endocrine therapy for advanced breast cancer.
• Lilly submitted Phase 3 lebrikizumab results in hand and foot atopic dermatitis to the FDA for a potential label update.
• Lilly announced Patrik Jonsson would retire at the end of 2026, and Ilya Yuffa would assume Lilly International responsibilities in a newly created president of Lilly Global Markets role.
• Lilly expected to share more pipeline details at its Innovation Day on December 7.